Skip to main content
. Author manuscript; available in PMC: 2019 Oct 11.
Published in final edited form as: Obesity (Silver Spring). 2019 Apr 1;27(5):803–812. doi: 10.1002/oby.22440

Figure 2.

Figure 2.

BD improves hyperglycemia and glucose tolerance in WT mice, but not in FXRko mice (N = 5 each group). (A) LFD-fed FXRko mice develop hyperglycemia. Fasting blood glucose levels, WT-LFD vs. FXRko-LFD, p < 0.001; WT-HFD vs. FXRko-HFD, p = 0.05. (B) HFD impairs oral glucose tolerance (OGTT) in both WT and FXRko mice. (C) Areas under curve (AUC) of OGTT. (D) BD decreases fasting blood glucose levels in HFD-fed WT (p < 0.01) and in HFD-fed FXRko mice (p = 0.05). However, when WT-BD vs. FXRko-BD, p = 0.018. (E) BD improved glucose tolerance in HFD-fed WT and HFD-fed FXRko mice. (F) AUC of OGTT. WT-HFD vs. WT-BD, p < 0.001; FXRko-HFD vs. FXRko-BD, p < 0.05, and WT-BD vs. FXRko-BD, p = 0.004.